Skip to main content

Northwest Biotherapeutics, Inc.

corporate_fare Company Profile

Northwest Biotherapeutics, Inc.

NWBO·OTC·Life Sciences·CIK 0001072379

We are a biotechnology company focused on developing personalized immune therapies for cancer. We have developed a platform technology, DCVax®, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. Our lead product, DCVax®-L, is designed to treat solid tumor cancers where the tumor can be surgically removed. We completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM), published the results in the JAMA Oncology peer-reviewed journal, and on December 20, 2023, submitted a Marketing Authorization Application (MAA) for commercial approval in the U.K. Our second product, DCVax®-Direct, is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed, which included treatment of more than a dozen types of cancers. As of December 31, 2025, we hold 58 issued patents, including national validations in certain European countries, and 50 pending patent applications worldwide, grouped into 8 patent families. Of these, 47 issued patents, including validations in European countries, and 29 pending patent applications directly relate to our DCVax products. In the United States and Europe, some of our patents and applications relate to compositions and the use of products, while others relate to aspects such as manufacturing. For example, in the United States, we have two issued patents and four pending patent applications that relate to the composition and/or use of our DCVax products.

Northwest Biotherapeutics, Inc. (OTC:NWBO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 14 items for NWBO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 8/10. Across its 14 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for NWBO spans 10-Q, 8-K, 424B5, 10-K.

Recent high-impact activity:

  • NW Bio Q3 Loss $28.8M, Cash Down to $725K, Going Concern Reaffirmed
  • NW Bio Raises $5.5M in Streeterville Debt With 10% OID and 8% Interest
  • NW Bio Partners with UK NHS Blood and Transplant to Scale DCVax-L Production
  • NW Bio's Q2 Loss, Going Concern Warning, and Heavy Dilution
  • NW Bio Lands $4.9M Convertible Note and $50M Standby Equity Facility with Yorkville

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$1.38M
Net Income
-$60.16M
Diluted EPS
-$0.04
Op. Cash Flow
-$44.76M
Free Cash Flow
-$46.27M
Operating Income
-$59.91M
Cash & Equivalents
$3.04M
Total Debt
$60.04M
Debt / Equity
-1.00×
Net Margin
-43.66×
Shares Outstanding
1.56B sh
Source: 10-K · filed 2026-04-15 · accession 0001104659-26-043806

Short Interest & Short Volume

7.78 days to cover

FINRA reported short interest of 69,421,915 shares in NWBO as of the October 30, 2026 settlement, a 5.1% decrease from the prior period — about 7.8 days to cover at its recent average daily volume. On November 20, 2026, 57.2% of NWBO volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)69,421,915 shares as of October 30, 2026
Change vs prior period▼ 5.1%
Days to cover7.78 at avg daily volume of 8,922,580
Daily short volume (FINRA facilities)57.2% of 5,533,338 shares on November 20, 2026
5-day average short volume56.2%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for NWBO, detected from its recent SEC filings · based on capital-structure filings through 2026-07-31.

1 recent capital raise

$4.9M Convertible Note with Yorkville · 40.3M Shares Registered for Conversion & Warrants

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with N →
$0.139
52-week range · as of 2026-11-13 $0.1381 – $0.3389
Market cap
$229.21M
Volume
5.5M (1.1× avg)
3-mo avg 5.1M
Live data · 2026-11-22 09:01 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed NWBO - Latest Insights

NWBO
Nov 13, 2026, 4:36 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.1565
Real-time Price: $0.139 info
Change: -$0.0175 (-11%) info
Market Cap: $229.214M info
NWBO
Oct 30, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.170
Real-time Price: $0.139 info
Change: -$0.031 (-18%) info
Market Cap: $229.214M info
NWBO
Oct 08, 2026, 5:15 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $0.148
Real-time Price: $0.139 info
Change: -$0.0090 (-6%) info
Market Cap: $229.214M info
NWBO
Aug 14, 2026, 4:17 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.192
Real-time Price: $0.139 info
Change: -$0.053 (-28%) info
Market Cap: $229.214M info
NWBO
Jul 31, 2026, 5:17 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.164
Real-time Price: $0.139 info
Change: -$0.025 (-15%) info
Market Cap: $229.214M info
NWBO
Jul 31, 2026, 5:15 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $0.164
Real-time Price: $0.139 info
Change: -$0.025 (-15%) info
Market Cap: $229.214M info
NWBO
Jul 17, 2026, 7:48 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.154
Real-time Price: $0.139 info
Change: -$0.015 (-10%) info
Market Cap: $229.214M info
NWBO
May 15, 2026, 4:53 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $0.2525
Real-time Price: $0.139 info
Change: -$0.1135 (-45%) info
Market Cap: $229.214M info
NWBO
May 15, 2026, 4:34 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $0.2525
Real-time Price: $0.139 info
Change: -$0.1135 (-45%) info
Market Cap: $229.214M info
NWBO
Apr 15, 2026, 4:25 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.19988
Real-time Price: $0.139 info
Change: -$0.06088 (-30%) info
Market Cap: $229.214M info
NWBO
Apr 15, 2026, 4:16 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $0.19988
Real-time Price: $0.139 info
Change: -$0.06088 (-30%) info
Market Cap: $229.214M info
NWBO
Apr 07, 2026, 12:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.2001
Real-time Price: $0.139 info
Change: -$0.0611 (-31%) info
Market Cap: $229.214M info
NWBO
Jan 15, 2026, 5:06 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.2925
Real-time Price: $0.139 info
Change: -$0.1535 (-52%) info
Market Cap: $229.214M info
NWBO
Jan 02, 2026, 5:15 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.2549
Real-time Price: $0.139 info
Change: -$0.1159 (-45%) info
Market Cap: $229.214M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets